分类: health

  • US reports first two deaths linked to  ‘explosive diarrhoea’ outbreak

    US reports first two deaths linked to ‘explosive diarrhoea’ outbreak

    A nationwide parasitic outbreak that has sickened thousands of people across the United States has claimed its first confirmed lives, Michigan state health officials announced this week. Two people in Michigan, the state at the center of the ongoing cyclospora outbreak, have died from complications tied to the infection, marking the first reported fatalities in this widespread public health incident.

    State health authorities shared that both deceased individuals lived with significant pre-existing chronic health conditions, which may have been severely exacerbated by cyclosporiasis infection and subsequent dehydration. No further personal or demographic details about the victims have been released to the public at this time.

    Data from the U.S. Centers for Disease Control and Prevention (CDC) shows the foodborne outbreak has already reached 45 U.S. states, with close to 7,000 cases formally confirmed through laboratory testing. In Michigan alone, state records track more than 11,000 suspected cases and 193 hospitalizations, though a large share of those cases have not received laboratory confirmation. Despite the large number of infections across the country, CDC officials emphasize that cyclospora-related deaths are extremely rare. The parasite is not typically classified as a life-threatening threat for most otherwise healthy people.

    Cyclospora cayetanensis, the heat-loving parasite responsible for the outbreak, infects the human intestinal tract and spreads through fecal contamination of food or water supplies. Historically, most outbreaks have been traced back to fresh fruits and vegetables that were irrigated with water contaminated with fecal matter.

    Public health investigators have officially linked this year’s widespread outbreak to leaf lettuce imported from a Taylor Farms processing facility in central Mexico, a major supplier that distributes produce to countless food service operations and restaurants across the U.S. In response to the outbreak connection, major U.S. fast-food chain Taco Bell moved quickly to remove all lettuce sourced from this Mexican facility from its menus nationwide. Taylor Farms has also implemented a voluntary recall of all lettuce harvested from its central Mexico growing operations.

    The outbreak has drawn international attention as well: UK health authorities have issued a public warning to travelers returning from the U.S. after documenting a small number of cases among recent visitors who fell ill after their trip.

    To reduce public risk of infection, the CDC is urging consumers to wash all fresh produce under running tap water, even products that are marketed and labeled as pre-washed. The agency notes, however, that standard washing practices may not fully eliminate the parasite from contaminated produce. For full decontamination, the CDC recommends cooking all fresh produce to an internal temperature of at least 70°C (158°F), a step that reliably kills the cyclospora parasite.

  • More pregnant women are dying in Congo as they avoid hospitals over Ebola

    More pregnant women are dying in Congo as they avoid hospitals over Ebola

    In the eastern Congolese city of Bunia, the epicenter of the Ebola outbreak declared in mid-May, 26-year-old expectant mother Esther Lutula made a fateful decision not long after public health authorities announced the crisis: she halted all her routine prenatal checkups. Like many residents across Ituri province, Lutula clung to a widespread dangerous misconception—she believed any visit to a health facility that resulted in a fever reading would lead to immediate involuntary isolation. That fear has kept her away from care, with Lutula telling the Associated Press she will only resume checkups once the virus is no longer circulating widely.

    But public health experts warn this choice is far from harmless; it can be deadly. New data from the United Nations Population Fund (UNFPA) reveals that maternal mortality across Ituri has doubled in the months since the outbreak began, a devastating secondary crisis unfolding alongside the rapidly spreading Ebola epidemic. Before the outbreak was declared in May, the province recorded an average of 3.1 maternal deaths per week. From May 25 to July 19, that average surged to 5.8 deaths weekly. Most alarmingly, the share of maternal deaths that occur outside of formal health facilities has nearly doubled too, jumping from 9.1% to 17.4% over the same period.

    This public health catastrophe is unfolding against a grim global backdrop: sub-Saharan Africa already bears 70% of the world’s maternal deaths, with roughly 180,000 preventable pregnancy-related deaths recorded across the continent each year. Congo, for its part, ranks among the most dangerous countries in the world to give birth. The latest United Nations data shows 19,000 Congolese women died from pregnancy complications in 2023, putting the country second only to Nigeria globally, tied with India.

    As Congo battles the fastest-growing Ebola outbreak on record, which has already claimed more than 1,600 confirmed lives, aid and health workers are sounding the alarm about this largely unreported shadow crisis: widespread fear and misinformation have driven thousands of pregnant women to avoid hospital care entirely, pushing an already catastrophic maternal mortality rate even higher. Noemi Dalmonte, UNFPA’s deputy country representative in Congo, explained that while avoidance of health facilities during public health emergencies is not uncommon across the continent due to safety concerns, Ebola’s unique reputation and the flood of misinformation surrounding it have amplified this trend dramatically.

    Many residents in the remote, conflict-riven region question whether Ebola even exists, while overstretched health workers struggle to mount an effective response with extremely limited supplies. For pregnant women, this has translated to a drastic reduction in access to life-saving care. Violence targeting outbreak response operations has only deepened fears: multiple Ebola treatment centers have been attacked by local residents fueled by misinformation and anger over strict public health measures, leaving many women afraid to seek care even for life-threatening pregnancy complications.

    The impact of this avoidance is visible on the ground at local health facilities. At Bénédicte Clinic in Bunia, Dr. Sonny Mwembo, the clinic’s medical director, reports that the number of women registering for prenatal care has plummeted from an average of 60 per month to just around 10. Even after weeks of targeted outreach to correct misinformation, many residents still cling to false beliefs about the outbreak. Elodie Yabiri, a heavily pregnant Bunia resident, summed up the common fear: “Right now, if you feel sick and go to the hospital, they say it’s Ebola and they put you in quarantine right away. That’s what scares people.” Yabiri added that she is avoiding hospitals as much as possible, relying only on the movement of her unborn child to gauge that her pregnancy is progressing safely.

    Compounding the crisis, Congo’s already overburdened, underfunded healthcare system has shifted most of its limited resources to Ebola response operations, leaving even fewer services for pregnant women who are still willing to seek care. Health facilities across the five provinces affected by the outbreak have redirected staff and medical supplies to Ebola containment efforts, cutting access to routine and emergency maternal care. The crisis has also gutted the local health workforce: at least 44 health workers have died from Ebola infection, and many more have walked off the job over unpaid salaries. Since the outbreak was declared in mid-May, at least 12 attacks on health facilities and response teams have been recorded across the region. Dr. Ghislain Maneba, an epidemiologist and community investigator working in Ituri’s Rwampara health zone, described the impossible conditions frontline workers face: “We are doing everything we can to make the public understand how dangerous this disease is. We are working day and night without being paid.”

    Pregnant women face uniquely elevated risks throughout this outbreak, on multiple fronts. Ebola is a rare but highly contagious, often fatal virus that spreads through contact with bodily fluids and contaminated materials. Women make up the majority of family caregivers when a loved one falls ill, and many are also serving on the frontlines of the outbreak response—including many pregnant health workers, AP journalists reporting on the outbreak have observed. “It is very important that they know how to protect themselves, that they have the right information,” Dalmonte said.

    The U.S. Centers for Disease Control and Prevention notes that pregnant women who contract Ebola face a significantly increased risk of life-threatening complications, including miscarriage. But for many women in eastern Congo, the greatest threat is not the virus itself—it is the lack of access to the care that could save their lives. Dalmonte summed up the dual crisis: “Pregnant women who delay care and avoid health facilities could die not from Ebola itself but because the care that would have saved them was no longer accessible, trusted or safe.”

    This reporting is part of an AP series on maternal mortality in sub-Saharan Africa, with financial support for global health and development coverage provided by the Gates Foundation. The AP retains full editorial control over all content.

  • New PBS drug for brain cancer two months after Richard Scolyer’s death

    New PBS drug for brain cancer two months after Richard Scolyer’s death

    Two months after the passing of iconic Australian cancer researcher Richard Scolyer, a long-awaited breakthrough treatment for one of the most prevalent adult brain cancers has been added to Australia’s Pharmaceutical Benefits Scheme (PBS), marking the first new approved option for the condition in more than two decades.

    On Saturday, Voranigo (generic name vorasidenib) became accessible through the national drug subsidy program for eligible Australian patients diagnosed with Grade 2 IDH-mutant glioma. This specific form of brain cancer is the most common diagnosis among adults under 50, with most patients receiving their diagnosis between the ages of 20 and 45. While slow-growing, the disease is currently incurable, and it gradually progresses over years, causing severe long-term impairment for those living with it.

    Australian Health Minister Mark Butler emphasized the profound burden this cancer places on patients, noting that it robs young adults of their health and quality of life at the peak of their working and personal lives. “It’s deeply, deeply debilitating,” Butler explained in an interview with News24. “Patients often live with repeated seizures, gradual cognitive decline, and permanent physical disability. Tragically, it hits people in very young adulthood, usually in their 20s and 30s.”

    Before this PBS listing, eligible patients would have been forced to pay up to $28,000 per month out of pocket to access the treatment – a sum Butler confirmed is well out of reach for the vast majority of Australian households. Now, thanks to the national subsidy, patients will only pay the standard PBS co-payment for the drug. Officials estimate approximately 130 patients will be able to access this life-changing treatment immediately following the listing.

    This new drug listing is part of a broader round of PBS updates rolled out in August, which also added new subsidized treatments for thyroid cancer, blood cancer, and Crohn’s disease, expanding access to critical care for thousands of Australians living with chronic and terminal conditions.

    The announcement carries particular emotional weight, coming just eight weeks after the death of Professor Richard Scolyer, a pioneering cancer researcher whose work transformed global melanoma treatment. Born in Tasmania, Scolyer received his own diagnosis of aggressive grade 4 glioblastoma in June 2023, just months after being named 2024 Australian of the Year alongside his long-time research collaborator Georgina Long. The pair had spent decades leading groundbreaking work to improve immunotherapy outcomes for melanoma patients before Scolyer’s cancer progressed earlier this year. He died on June 7 at the age of 59, leaving behind a legacy of advocacy for expanded access to innovative cancer treatments.

  • Why Uganda seems to be winning the battle against Ebola as virus spreads in DR Congo

    Why Uganda seems to be winning the battle against Ebola as virus spreads in DR Congo

    A devastating Ebola outbreak in eastern Democratic Republic of Congo has reached a grim new threshold, with official fatalities surpassing 1,500 to make it the second-worst Ebola event recorded in modern history. Declared publicly this past May, public health experts warn that the actual death toll is far higher than the official count, and Congolese authorities confirmed last Thursday that the virus is spreading at a faster rate than any previous outbreak the country has faced.

    Just across the border, however, Uganda’s experience of the same cross-border outbreak paints a dramatically different picture of successful containment. Two weeks ago, the East African nation discharged its final active Ebola patient from care, a moment the country’s health minister described as a “moment of joy.” In total, Uganda recorded just 20 confirmed cases and only two deaths from the virus – a outcome that was not a stroke of luck, according to senior global health officials.

    “This is not by luck or chance. It is because people invested in preparedness,” explained Dr Kasonde Mwinga, the World Health Organization’s country representative for Uganda, in an interview with the BBC.

    For half a century, DR Congo has borne the brunt of Ebola outbreaks, recording 17 separate events since the virus was first identified. Uganda, by comparison, has faced nine outbreaks since 2000, and government officials say decades of hard-won experience have given the country a playbook to stop transmission before it can spiral into a larger crisis.

    A 2011 incident in Uganda’s central Luwero district illustrates this advantage. When a 12-year-old girl arrived at a local hospital with telltale Ebola symptoms, clinicians immediately moved to isolate her, donned full personal protective equipment for all interactions, and safely handled her remains after she died just three hours after admission. Those quick precautions stopped transmission in its tracks, before the virus could spread to other patients or healthcare workers, even before lab tests confirmed the diagnosis.

    “We know Ebola. It has been here a few times, we know how to deal with it,” government spokesperson Alan Kasujja told BBC’s Newsday.

    Uganda’s first confirmed case in the current cross-border event was a Congolese man who crossed the border to seek medical care. After DR Congo confirmed multiple imported cases originating from its territory, Ugandan health authorities immediately activated a pre-built specialist Ebola treatment center at Kampala’s Mulago Hospital, a facility that was already set up following a 2023 Ebola outbreak. The center already retained leftover medical supplies and maintained a standing emergency response team, meaning the facility was ready to accept patients within 24 hours of activation, according to Dr David Kaggwa, the center’s head.

    “It was a matter of sorting and ordering a few more supplies, and then actually in one day we were ready to receive the patients. So, it is easy, it’s not that we’re starting from scratch,” Kaggwa said.

    Fifteen of Uganda’s 20 confirmed cases were imported from DR Congo. After the two countries issued a joint public declaration of the outbreak on May 15, residents with Ebola symptoms – including fever, headache, and vomiting – began seeking care directly at the specialized treatment unit, rather than passing through crowded general hospitals, Kaggwa explained. This immediate routing cut off opportunities for community transmission by limiting contact between infected people and the general public.

    To further block spread, Ugandan authorities also closed the shared border with DR Congo, accepting the unavoidable economic hit to cross-border traders who rely on daily movement between the two countries to make a living.

    Beyond pre-existing preparation, Uganda also benefited from early awareness of the outbreak’s specific character. Before DR Congo confirmed its first cases, the virus spread undetected for weeks: local health officials were testing for common Ebola strains, but the current outbreak is caused by the rare Bundibugyo strain, delaying detection. By the time the outbreak was declared, the virus had already gained a foothold in Congolese communities, giving Uganda advance warning to activate its response before the virus reached its territory.

    “Surveillance mechanisms were put in place then it was easy to identify all the patients quickly,” Kaggwa said.

    In DR Congo, systemic challenges have hampered surveillance and contact tracing efforts that are critical to stopping Ebola. A field investigator working in Bunia, the city at the outbreak’s epicenter, told Reuters that poor planning, logistical backlogs, and reliance on under-trained staff have left response teams constantly playing catch-up.

    “We discover the disease only after it has already spread. We’re just chasing it,” said Dr Moubarack Kano.

    Chronic insecurity in eastern DR Congo has compounded these challenges. Ituri province, the current epicenter, has been under military rule for years as government forces battle dozens of active armed groups, while large swathes of territory further south are controlled by the M23 rebel militia. While M23 claims to have contained local transmission through early detection, mass displacement caused by ongoing conflict has left millions of people moving across the region, creating gaps in surveillance that the virus exploits. Cross-border trade and artisanal mining also drive constant population movement, giving the virus more opportunities to jump between communities and across borders.

    In contrast, Uganda successfully completed full 21-day quarantine periods for more than 6,000 known contacts of confirmed Ebola cases, a step that Kaggwa says was critical to halting transmission, since most secondary cases emerge from known exposed contacts.

    “I would say that our success is mainly due to our promptness and completeness of follow-up,” Kasujja concurred.

    This successful containment is not the first time Uganda has earned international recognition for its proactive public health response. In the 1990s and 2000s, the country drew widespread praise for cutting national HIV prevalence from over 10% to 6% in a decade through a large-scale public education campaign centered on the “ABC” prevention framework: abstinence, being faithful, and condom use.

    Community buy-in has also been a core pillar of Uganda’s success, Kasujja added. Even after the country was declared Ebola-free, the public continues to follow recommended prevention precautions, he said.

    This level of community cooperation is seen in the experience of one of Uganda’s early cases: a nurse who contracted Ebola while working in a Kampala intensive care unit, shortly before the outbreak was officially declared. She had treated a patient who later died of Ebola without anyone knowing the cause of death, and when she developed symptoms two weeks later and learned two of her colleagues had already tested positive, she voluntarily entered isolation immediately. Even when her 11-month-old breastfeeding infant was separated from her for a 21-day quarantine, she continued to fully comply with all public health guidelines.

    Uganda broke standard World Health Organization protocol by declaring itself Ebola-free just two weeks after discharging its last patient, instead of the recommended 42-day waiting period. The health ministry justified the early announcement by noting all cases were imported from DR Congo, and no unexplained community transmission ever occurred within Uganda’s borders.

    Even with this success, Ugandan officials are under no illusion that the threat has passed. The country shares a long, porous border with Ituri province, the heart of the Congolese outbreak, meaning the virus can easily re-enter Uganda at any time.

    In response, Uganda has deployed dozens of healthcare workers across the border to support DR Congo’s response, with Health Minister Chris Baryomunsi writing on social media platform X that the country is standing with its “brothers and sisters” to tackle the shared threat.

    “We are going to where the problem is. Uganda cannot win against Ebola if the Democratic Republic of Congo fails,” Kasujja explained.

    Uganda has also ramped up screening at border crossings and continues to run public education campaigns on Ebola prevention and response protocols. “We’re always very prepared,” Kaggwa said.

  • Current Ebola outbreak worst ever in DR Congo, WHO says

    Current Ebola outbreak worst ever in DR Congo, WHO says

    The World Health Organization has confirmed that the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC) has become the largest in the nation’s recorded history, with case numbers continuing to climb at an alarming rate months after the outbreak was first declared.

    As of July 30 this year, national and global health authorities have documented 3,605 confirmed Ebola infections, with 1,587 people dying from the virus – putting the current fatality rate at 44 percent. This outbreak, which was officially announced on May 15, 2026, is driven by the Bundibugyo strain of Ebola, and has already exceeded the size of the previous largest DRC outbreak recorded between 2018 and 2020, which registered just under 3,500 total cases. That earlier outbreak, caused by a different strain, recorded roughly 2,300 fatalities.

    Unlike more widely studied Ebola strains, there are currently no formally approved vaccines or targeted treatments available for the Bundibugyo variant, a gap that has made controlling the outbreak far more challenging. However, research teams in the United Kingdom and Singapore are actively advancing candidate vaccine development, with the WHO naming a candidate being developed in Singapore as the most promising for rapid deployment. Clinical trials for a second potential vaccine have already launched in the UK.

    In a public statement posted to the social platform X, the WHO warned that the outbreak is intensifying, with sustained community transmission driving consistent increases in both new cases and deaths. In the seven days leading up to July 30, the outbreak hit a new grim milestone: 567 new confirmed cases and 296 deaths, the highest weekly caseload recorded since the outbreak began. WHO officials noted that these numbers highlight the exceptional speed at which the virus is spreading through vulnerable populations.

    Multiple overlapping challenges are severely hampering international and local response efforts, health officials say. The outbreak is centered in DRC’s northeastern Ituri Province, which shares borders with South Sudan and Uganda. It has since spread to neighboring North and South Kivu provinces, large swathes of which are controlled by the M23 armed group, a militia supported by Rwanda. Chronic insecurity, mass population displacement from conflict zones, unregulated cross-border movement, and limited access to affected communities have all combined to slow emergency response work and raise the risk of the virus spreading further afield.

    To date, the outbreak has crossed international borders: 20 confirmed cases have been recorded in Uganda, one case has been reported in France, and two Congolese patients have been transferred to Germany for treatment. Over the past half-century, Ebola – which spreads through direct contact with infected bodily fluids – has killed more than 15,000 people across the African continent, with most major outbreaks concentrated in Central Africa.

  • Seagull tests positive to bird flu as calls grow for $200m wildlife fund

    Seagull tests positive to bird flu as calls grow for $200m wildlife fund

    Australia’s two-year battle to contain the spread of highly pathogenic H5 bird flu has entered a deeply concerning new stage, after a common Australian seagull — a species seen daily on beaches and coastal communities across the country — tested positive for the virus, prompting environmental and health officials to warn the pathogen is now permanently established in the nation’s wildlife populations.

    The confirmation of the seagull infection comes on the heels of a cascade of new detections across multiple Australian states, marking a clear shift of the virus beyond isolated populations of rare wild seabirds into ubiquitous native species. Invasive Species Council chief executive Jack Gough described the positive test result as a definitive watershed moment for the outbreak that changes the entire trajectory of Australia’s response.

    “One of the most widespread, recognizable seabirds on our coastlines is now infected, and the federal government has acknowledged that this deadly strain is here to stay,” Gough stated in a media briefing Friday. “When pelicans and seagulls begin dying in massive numbers on beaches that communities visit every day, public attitudes toward wildlife disease management and environmental protection will shift far faster than many politicians anticipate.”

    Gough has issued an urgent call for the federal government to allocate a minimum $200 million wildlife resilience fund to address the coming crisis, warning that underinvestment would leave the nation unprepared for a wave of wildlife mortality. “Anything less than this amount is a failure to take seriously the tsunami of destruction that is about to hit our iconic native birds and coastal marine mammals,” he said.

    The seagull detection follows a string of new confirmations that have accelerated alarm across the country. On Thursday, Victoria recorded its first ever H5 bird flu case in a wild bird, a greater crested tern found in Portland, the state’s western coastal region. This detection came just 24 hours after South Australian health authorities confirmed the first instance of local transmission of the virus between wild birds in the state. By Thursday, more than 13 wild birds had tested positive across South Australia, with cases detected at the popular Seal Bay conservation area on Kangaroo Island and the coastal town of Robe.

    As of earlier this week, Australia had recorded 27 confirmed H5 cases in wild seabirds spread across five states: 10 in Western Australia, 14 in South Australia, two in New South Wales, and one in Queensland. The most recent detections push that total even higher, with more test results pending from across the country’s southern coastline.

    Addressing reporters in Hobart on Friday, Federal Agriculture, Fisheries and Forestry Minister Julie Collins offered one key reassurance for the public and industry: there remains no evidence the virus has spread to commercial poultry operations or entered Australia’s agricultural supply chain. “We have no evidence of it being in our poultry or agricultural system, and the risk to human health remains very low,” Collins said.

    When asked whether Australians would need to adjust to permanent coexistence with the virus, Collins confirmed that global experience matches the expert advice Australia has received: the H5 strain cannot be eradicated once it becomes established in wild wildlife populations. “Overseas experience has shown this is the reality, and our experts agree that full eradication from wildlife is not possible,” she said.

    The minister added that the federal government will continue coordinating with industry groups, wildlife veterinarians, and disease specialists to slow the spread of the virus, while urging both commercial poultry producers and owners of backyard flocks to immediately strengthen their biosecurity protocols. “Our biosecurity is our strongest defense against this virus,” Collins emphasized. “Detailed, up-to-date guidance is available on birdflu.gov.au, but the single most effective step owners can take is strengthening on-property biosecurity. This means preventing domestic birds from interacting with native birds and wild wildlife, and ensuring clean, uncontaminated water and food supplies at all times.”

    Australia’s chief veterinary officer Beth Cookson noted earlier this week that the spread of the virus into common coastal species was not unexpected. “It was never a surprise that we would begin to see local transmission among birds that share the same coastal habitats,” Cookson said. “Confirmation of local transmission does mean we can expect to see wider spread across wild bird populations and other vulnerable wildlife species going forward.”

    Cookson added that global data makes clear the long-term trajectory of the outbreak: “We know from decades of experience overseas that once the virus becomes widespread in wild bird populations, we cannot avoid some level of mortality among susceptible wildlife in their natural habitats. Our focus right now remains on expanded surveillance to map where the virus is circulating, and to take targeted action to reduce its impact on vulnerable native species wherever possible.”

    Prior to the current outbreak, Australia was the last inhabited continent free of H5 bird flu. Researchers and health officials link the arrival of the virus to migratory seabirds traveling to Australian coastal habitats from Antarctic and sub-Antarctic breeding grounds over the past year.

  • Death toll tops 1,500 in fastest-growing Ebola outbreak in history, Congo says

    Death toll tops 1,500 in fastest-growing Ebola outbreak in history, Congo says

    BUNIA, Democratic Republic of Congo — The world’s most rapidly expanding Ebola outbreak on record has crossed a devastating milestone, with new official data released Thursday confirming more than 1,500 fatalities in eastern Congo. The sharp death toll increase — a 50 percent jump logged over roughly one week — underscores that the spread of the virus continues to outpace international and local response measures.

    Updated statistics from the Congolese government show that as of Tuesday, the ongoing outbreak has recorded a total of 3,442 confirmed and probable cases, with the death count climbing to 1,521. First declared on May 15, this outbreak differs sharply from most prior Ebola events in a key, dangerous way: it is caused by the Bundibugyo strain, for which no specific, fully approved vaccines or antiviral treatments currently exist.

    The speed and mortality of this outbreak have already outstripped every previous Ebola event in recorded history, including the devastating 2014-2016 West African epidemic that long held the title of the world’s worst Ebola outbreak. That crisis, which ultimately killed more than 11,000 people across at least 28,000 recorded cases, took roughly eight months to reach 1,000 deaths. This outbreak has reached 1,500 deaths in a far shorter timeframe.

    Ebola is an uncommon but highly contagious viral illness, transmitted through direct contact with infected bodily fluids including blood, vomit, and semen. The disease it causes progresses rapidly, with severe symptoms that lead to death in a large majority of cases without prompt, specialized care.

  • AstraZeneca reverses decision to pull lifesaving cancer and endometriosis drug Zoladex

    AstraZeneca reverses decision to pull lifesaving cancer and endometriosis drug Zoladex

    Following intense public and patient advocacy that gathered tens of thousands of signatures, pharmaceutical giant AstraZeneca has reversed its plan to fully pull the monthly 3.6mg dose of lifesaving drug Zoladex from the Australian market, announcing Friday it will provide the hormone-suppressing treatment free of charge to eligible patients starting November 2026.

    Zoladex, generic name goserelin, is a core treatment for multiple serious conditions: it lowers sex hormone levels to slow the growth of prostate cancer in men, and treats breast cancer and severe endometriosis in women. The 3.6mg monthly implant, which delivers a steady dose of the drug via a small pellet injected under the skin, was previously listed on Australia’s Pharmaceutical Benefits Scheme (PBS), the federal government’s subsidized drug program that makes critical medications affordable for patients.

    In a statement explaining the original planned withdrawal, AstraZeneca noted that the current pricing structure of the PBS made continued supply of the 3.6mg dose through the scheme financially unsustainable, as the subsidized price offered by the program was too low to support ongoing production and distribution. The company had initially scheduled the dose to be removed from both the PBS and the private Australian market entirely this November, a decision that sparked immediate and widespread outrage from patients, clinicians and cancer advocacy groups.

    Patients launched a public Change.org petition demanding AstraZeneca reverse its withdrawal and create a clear transition plan for people relying on the drug for ongoing care. The petition quickly went viral, racking up more than 40,000 signatures and more than 20,000 shares across social media. “No one should find out through the news that a medication forming part of their treatment plan may be taken away,” the petition read. “No patient should be left wondering whether their care will be interrupted. No doctor should be forced into rushed treatment changes because of a corporate decision.”

    The pressure campaign pushed AstraZeneca to revise its plan. Under the new continuity program, patients who do not have a suitable alternative treatment pathway will still be able to access the 3.6mg monthly implant for free starting November 2026. While the reversal has been welcomed by patients, key cancer advocacy groups and clinical leaders warn the arrangement is not a permanent or sustainable solution.

    Breast Cancer Network Australia (BCNA), one of the country’s leading patient advocacy organizations, issued a statement noting that critical questions around long-term access, administrative practicality and long-term cost stability remain unanswered, creating ongoing uncertainty for thousands of vulnerable patients. “While this update offers some guidance on how eligible patients might continue accessing the monthly option once it is off the PBS, it isn’t a long-term fix,” the group said.

    Currently, a higher 10.8mg dose of Zoladex, which only needs to be administered once every three months, is available on the private market, but it is not covered by PBS subsidies. Following the public backlash over the 3.6mg withdrawal, AstraZeneca has submitted an application to add the higher 10.8mg dose to the PBS scheme. Even so, clinical leaders argue that the entire situation highlights the risk of allowing global corporate commercial decisions to undermine evidence-based best practice care for Australian patients.

    Jenny Gilchrist, an experienced breast oncology nurse, praised the unified advocacy efforts of clinicians and BCNA that pressured AstraZeneca to revise its plan, but emphasized the changes remain unacceptable for patients. “After the announcement that Zoladex 3.6mg was being withdrawn from the market, clinicians and Breast Cancer Network Australia stood together, moved quickly and spoke with one clear united voice. This is unacceptable,” Gilchrist said. “Global commercial decisions must not be allowed to undermine best practice care here in Australia.”

  • Red Cross declares crisis over blood supply shortage in US for second time its history

    Red Cross declares crisis over blood supply shortage in US for second time its history

    The American Red Cross, the United States’ largest blood provider, has issued a dire alert that national blood inventories have dropped to a historic crisis level — marking only the second time in the organization’s 141-year history that supplies have fallen this low. What makes this shortage particularly acute is that it has hit during the summer months, a period when demand for blood at hospitals already surges, driven by higher rates of outdoor activity, traffic accidents, and traumatic injuries that require urgent transfusions. Last month alone, available blood supplies fell by 25%, according to Dr. Courtney Lawrence, a medical leader with the American Red Cross, who spoke to the BBC about the unfolding emergency.

    Right now, the organization is distributing roughly 3,500 more units of blood weekly than it typically does at this time of year, forcing it to draw down reserves to critically low levels. Unlike many medical supplies, blood cannot be stockpiled long-term to offset shortages: red blood cells have a maximum shelf life of just 42 days before they degrade and become unusable. While all blood types are in urgent need of replenishment, demand is most pressing for O positive blood, the universal donor type that is critical for emergency care when a patient’s blood type is unknown.

    A perfect storm of overlapping crises has pushed a pre-existing mild shortage into a full-blown public health emergency, Dr. Lawrence explained. Record-breaking extreme heat across much of the U.S. has deterred potential donors from leaving their homes to attend donation events, and many planned blood drives at community and commercial sites have been unable to maintain cool, comfortable environments that meet donor safety standards. Widespread wildfires across North America have further strained logistics and diverted organizational resources away from donation outreach. Additionally, the country is currently facing an unusual outbreak of cyclosporiasis, a foodborne parasitic infection that causes severe gastrointestinal illness, which has ruled out many recently infected people from donating blood under existing safety guidelines.

    The only other time the American Red Cross has declared a blood supply crisis of this magnitude was in January 2022, when surging Covid-19 cases combined with brutal winter weather to collapse donation rates. The current crisis is already starting to impact patient care: hospitals that work with the Red Cross have reported that routine medical procedures may be disrupted, and some facilities are already evaluating whether they will need to redirect emergency trauma patients to other centers if they cannot maintain sufficient blood reserves to handle critical cases.

    The crisis is not limited to the United States. Neighboring Canada is also facing a significant drop in blood donations, with Canadian Blood Services reporting that donations have fallen nearly 20% since the start of June. Over the past six weeks, the organization has seen between 1,500 and 2,500 unfilled donation appointments every week, forcing it to draw on existing reserves to meet ongoing patient needs. While a small seasonal dip in summer donations is expected and accounted for in annual planning, the current decline has fallen far below typical seasonal patterns. Several blood types now have only a few days of reserve stock on hand, a situation that Canadian Blood Services warns is unsustainable for long-term patient care unless donation trends reverse quickly. Unlike in the U.S., Canadian health officials have not identified a clear set of causes for the unexpected drop in donor turnout.

  • Australian-first Alzheimer’s blood test launched in Sydney with results in 18 minutes

    Australian-first Alzheimer’s blood test launched in Sydney with results in 18 minutes

    Australia is on the cusp of a transformative shift in Alzheimer’s disease care, with the launch of a pioneering new blood test that can detect early signs of the condition up to two decades before patients begin showing noticeable symptoms. Developed as part of a new collaborative initiative between Neuroscience Research Australia (NeuRA) and Roche Diagnostics Australia, the test will anchor the newly launched Asia-Pacific Centre of Excellence for Alzheimer’s Disease Diagnosis in Sydney, formally opened by Federal Minister for Health and Ageing Mark Butler.

    For decades, one of the most intractable barriers to effective Alzheimer’s care has been delayed or uncertain diagnosis. Current gold-standard confirmation methods—PET brain scans and lumbar punctures to collect cerebrospinal fluid—are costly, invasive, and largely inaccessible outside major metropolitan centers. Many patients wait years for a definitive diagnosis, by which time disease-modifying treatments that work only in early stages are no longer effective. The new blood-based test upends this status quo: it delivers results in as little as 18 minutes, matches the accuracy of traditional testing methods, and can identify Alzheimer’s-related protein changes decades before cognitive symptoms emerge.

    Associate Professor Emma Devenney, a leading researcher on the project, explained that the test targets key biomarkers linked to Alzheimer’s pathology: pTau181, pTau217, and the ApoE4 genetic risk marker. “These blood-based biomarkers let us confirm the presence of the proteins that cause Alzheimer’s far earlier than current diagnostic pathways,” Devenney noted in an interview with NewsWire. “That early certainty is life-changing for patients. Right now, the average time from a patient first noticing symptoms to getting a dementia diagnosis is around three years—for some, it’s even longer. By that point, many can’t access the treatments that slow progression, which only work in early-stage disease.”

    The experience of Nell Hawe, a Port Macquarie grandmother living with young-onset Alzheimer’s, underscores the harm of diagnostic delay. Hawe first developed symptoms at age 48, but it took four years for her to receive a diagnosis, after doctors repeatedly dismissed her early cognitive changes as stress and menopause-related changes. “I could have started treatment years earlier, which might have slowed how quickly the disease progressed,” Hawe said. She is part of the *Think Again* public awareness campaign run by news.com.au and *The Australian*, and emphasized that early, accessible diagnosis would transform outcomes for thousands of Australian families. “The waiting for a diagnosis is the most frustrating part for so many people. A simple blood test that gives answers quickly is just amazing,” she added.

    Roche’s test has already secured a spot on Australia’s Therapeutic Goods Administration registry, marking one of the first approved Alzheimer’s blood tests in the country. For the immediate future, the test will be used primarily to confirm Alzheimer’s pathology for clinical trials run out of the new Sydney centre, but leaders of the project expect broader access for clinical use to become available over the coming months. The centre will also serve as an Asia-Pacific hub for dementia diagnostics research, working alongside partners Eli Lilly Australia to streamline diagnostic and treatment pathways, evaluate new biomarkers, and speed up the translation of emerging research into patient care.

    The launch comes as Australia and the broader Asia-Pacific region face an escalating dementia public health crisis. Dementia is already the leading cause of death in Australia, where more than 446,500 people currently live with the condition. Projections indicate that number will surpass 1 million by 2065, with the annual economic cost already exceeding $15.8 billion (corrected from the original $4.7 billion that referenced partial costs) and growing pressure on household caregivers and the public health system. Alzheimer’s accounts for 60 to 70 per cent of all dementia cases globally, yet an estimated 75 per cent of people living with the disease remain undiagnosed. For the Asia-Pacific region, which is home to 20 per cent of the global population, the burden is set to grow even faster: the region is expected to account for more than half of the world’s dementia cases by 2050.

    Long-term, the project’s leadership aims to secure Medicare coverage for the blood test, making it widely accessible to patients across regional and metropolitan Australia. For now, patients concerned about cognitive decline are advised to first consult their general practitioner, who can refer them to a specialist for testing once the centre is fully operational. Experts say the breakthrough lays the groundwork for a future shift from late-stage Alzheimer’s care to preventive intervention, a long-sought goal that could drastically reduce the global burden of the disease.